Peter D Scalia, MD | |
234 Industrial Way W Ste 103, Eatontown, NJ 07724-4244 | |
(848) 208-2055 | |
(848) 208-2078 |
Full Name | Peter D Scalia |
---|---|
Gender | Male |
Speciality | Thoracic Surgery |
Experience | 41 Years |
Location | 234 Industrial Way W Ste 103, Eatontown, New Jersey |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285633321 | NPI | - | NPPES |
5069602 | Medicaid | NJ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | MA45352 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Vna Of Central Jersey Home Care & Hospice | Toms river, NJ | Home health agency |
Hackensack Meridian Health At Home Ocean County | Brick, NJ | Home health agency |
Community Medical Center | Toms river, NJ | Hospital |
Ocean Medical Center | Brick, NJ | Hospital |
Jersey Shore University Medical Center | Neptune, NJ | Hospital |
Monmouth Medical Center | Long branch, NJ | Hospital |
Riverview Medical Center | Red bank, NJ | Hospital |
Entity Name | Jersey Shore Cardiothoracic And Vascular Surgery Associates Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1225187883 PECOS PAC ID: 6204983232 Enrollment ID: O20090409000112 |
News Archive
Researchers from the 'Angiogenesis signaling pathways' research group of the Institute of Biomedical Investigation of Bellvitge, led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3-kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs).
The negative impact of contractions during in vitro fertilisation is a well-known fact. What was unknown until now was the effect it had on artificial insemination.
Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.
Pacific Northwest National Laboratory has received a $10.3 million biodefense contract from the National Institute of Allergies and Infectious Agents (NIAID) to identify the proteins that regulate the bacteria that cause salmonella poisoning and typhoid fever, and the monkey pox virus.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Peter D Scalia, MD 234 Industrial Way W Ste 103, Eatontown, NJ 07724-4244 Ph: (848) 208-2055 | Peter D Scalia, MD 234 Industrial Way W Ste 103, Eatontown, NJ 07724-4244 Ph: (848) 208-2055 |
News Archive
Researchers from the 'Angiogenesis signaling pathways' research group of the Institute of Biomedical Investigation of Bellvitge, led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3-kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs).
The negative impact of contractions during in vitro fertilisation is a well-known fact. What was unknown until now was the effect it had on artificial insemination.
Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.
Pacific Northwest National Laboratory has received a $10.3 million biodefense contract from the National Institute of Allergies and Infectious Agents (NIAID) to identify the proteins that regulate the bacteria that cause salmonella poisoning and typhoid fever, and the monkey pox virus.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.
› Verified 6 days ago